AI Article Synopsis
- Upper gastrointestinal bleeding (UGIB) is a serious and common issue affecting many individuals in the U.S. and globally.
- Recent advancements in treating UGIB include the FDA approval of Hemospray and the use of video capsule endoscopy for patient assessment.
- The introduction of new reversal agents for blood thinners further enhances the management of this potentially life-threatening condition.
Article Abstract
Purpose Of Review: Upper gastrointestinal bleeding (UGIB) is a common and life-threatening condition in the United States and worldwide.
Recent Findings: There have been several exciting recent advances in the endoscopic management of UGIB. One such advance is the recent approval of Hemospray by US Food and Drug Administration in May 2018. Another one is the emerging role of video capsule endoscopy as a triage and localization tool for UGIB patients. Finally, the development of new reversal agents for antithrombotic medications is an important advance in the management of life-threatening upper gastrointestinal bleed.
Summary: In this article, we will broadly review the management of nonvariceal UGIB, focusing primarily on the data addressing these new advances.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MOG.0000000000000582 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!